Iran Launches Production Line of New Generation of Recombinant Vaccines
“Recombinant vaccines are the solution to biological crises in the country,” said Reza Bani Hashemi, the head of the Research and Development (R&D) Department of Razi Vaccine and Serum Research Institute (RVSRI), on the sidelines of a ceremony to launch the production line of the new generation of recombinant vaccines at Razi Institute.
He noted that the production line is the industrial scale-up site for the research, development and production of recombinant vaccines and the advanced adjuvants that did not exist in the country.
“One of the advantages of this site is the conversion of all recombinant vaccines to an industrial scale, and another positive point is the ability to turn ideas into products,” Bani Hashemi said.
“At this site, we are capable of bringing new generation of vaccines that are being produced in the world to the production stage at a higher speed than foreign producers,” he stated.
Iranian researchers have discovered several recombinant vaccine formulation for viral diseases so far.
In a relevant development in November, a team of researchers at a knowledge-based company in Iran achieved the formulation of a vaccine based on multi-epitope protein for AIDS and Covid-19 viral diseases, which was patented in the United States.
Dr. Maria Beihaqqi, the managing director of the knowledge-based company, located at Ferdowsi University of Mashahd in the Northeastern part of Iran said in an interview with local media that production of biotechnology products, diagnostic kits, smart polymeric drug delivery systems and biotechnology products are the research field of their company and said.
Regarding the biotechnology products of the knowledge-based company, she said, “This product is a recombinant protein based on cytokine genes attached to the CCR7 receptor. This recombinant protein was registered in the US Patent and Trademark Office.”
According to the researcher, this recombinant protein is considered a type of vaccine for viral diseases, and it has been patented in the United States under the title "Cytokine-based multi-epitope protein for binding to ccr7-positive cells".
She further said that the cytokine-based multi-epitope protein is used both for early diagnosis of cancer and for vaccine production.
“If a patient is in a condition when the doctor cannot diagnose his/her physical condition and underlying diseases, these kits can diagnose their diseases depending on the genes of the patient,” she went on to say.
4155/v
